Key Takeaways
- ZIVO Bioscience is launching a second collaborative study with the University of Delaware to explore algal-derived solutions for mitigating Low Pathogenicity Avian Influenza (LPAI) in poultry.
- The new study builds on prior research that demonstrated a reduction in viral shedding and delayed disease transmission among treated birds.
- Interest from global animal health companies underscores the potential of ZIVO’s non-antibiotic solutions for improving poultry health.
- The study aims to optimize formulations and treatment protocols for real-world poultry production environments.
- ZIVO’s research aligns with industry efforts to develop sustainable and natural alternatives to traditional poultry disease treatments.
ZIVO Bioscience’s New Study to Explore Algal-Derived Solutions for Poultry Health
ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech research and development company, has announced plans for a second collaborative study with the University of Delaware. The study will focus on evaluating the potential of ZIVO’s proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry.
ZIVO Bioscience Advancing Research on Avian Influenza Mitigation
ZIVO’s previous research with the University of Delaware demonstrated promising results, including a significant reduction in viral shedding and a delay in disease transmission among treated birds. This upcoming study aims to refine formulations and treatment protocols to improve the efficacy of ZIVO’s algal-derived active ingredients in real-world poultry production settings.
John Payne, Chairman and CEO of ZIVO Bioscience, highlighted the importance of the collaboration, stating, “The University of Delaware is a preeminent institution in animal science research, and we look forward to continuing our collaboration to advance understanding of how our active ingredients can combat avian influenza.”
Growing Industry Interest in Non-Antibiotic Solutions
The encouraging findings from ZIVO’s studies on avian influenza and coccidiosis have generated interest from global animal health companies. These companies are exploring innovative, non-antibiotic approaches to combat disease transmission, highlighting the potential for ZIVO’s proprietary compounds to enhance poultry health and productivity.
Payne emphasized the industry validation of ZIVO’s approach, stating, “The interest from leading animal health companies further validates our commitment to delivering sustainable, healthier solutions at cost parity to the poultry industry.”
Next Steps in ZIVO Bioscience’s Poultry Disease Research
The new study represents a continuation of ZIVO’s research efforts into avian influenza applications. By leveraging active compounds derived from proprietary algal cultures, the company aims to develop natural alternatives to traditional treatments, addressing key challenges such as cost and drug resistance.
“This newest study represents the next step in what we expect will be a series of studies to thoroughly evaluate the potential of ZIVO’s products in various avian influenza applications,” added Payne. “By developing effective, natural alternatives to traditional treatments, we hope to offer sustainable solutions for the poultry industry.”
As the study progresses, ZIVO Bioscience and the University of Delaware aim to generate insights that could contribute to broader applications in poultry disease management.
1 Comment